NO962637D0 - 2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler - Google Patents

2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler

Info

Publication number
NO962637D0
NO962637D0 NO962637A NO962637A NO962637D0 NO 962637 D0 NO962637 D0 NO 962637D0 NO 962637 A NO962637 A NO 962637A NO 962637 A NO962637 A NO 962637A NO 962637 D0 NO962637 D0 NO 962637D0
Authority
NO
Norway
Prior art keywords
nervous system
central nervous
pharmaceutical agents
salts
disulfonylphenylbutylnitrone
Prior art date
Application number
NO962637A
Other languages
English (en)
Other versions
NO962637L (no
NO306457B1 (no
Inventor
John M Carney
Original Assignee
Oklahoma Med Res Found
Univ Kentucky Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Med Res Found, Univ Kentucky Res Found filed Critical Oklahoma Med Res Found
Publication of NO962637D0 publication Critical patent/NO962637D0/no
Publication of NO962637L publication Critical patent/NO962637L/no
Publication of NO306457B1 publication Critical patent/NO306457B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/45—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/46—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO962637A 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament NO306457B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/173,579 US5488145A (en) 1993-12-23 1993-12-23 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
PCT/US1994/014545 WO1995017876A2 (en) 1993-12-23 1994-12-22 2,4-disulphophenyl butylnitrone, its salts, and their use as pharmaceutical spintraps

Publications (3)

Publication Number Publication Date
NO962637D0 true NO962637D0 (no) 1996-06-20
NO962637L NO962637L (no) 1996-08-13
NO306457B1 NO306457B1 (no) 1999-11-08

Family

ID=22632663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962637A NO306457B1 (no) 1993-12-23 1996-06-20 2,4-disulfonylfenylbutylnitron, salter derav, farmasöytisk sammensetning, samt anvendelse av denne forbindelse til fremstilling av et medikament

Country Status (29)

Country Link
US (4) US5488145A (no)
EP (1) EP0736004B1 (no)
JP (3) JP3412821B2 (no)
KR (1) KR100370522B1 (no)
CN (1) CN1070176C (no)
AT (1) ATE192736T1 (no)
AU (1) AU679835B2 (no)
BR (2) BR9408378A (no)
CA (1) CA2179521C (no)
CZ (1) CZ289629B6 (no)
DE (1) DE69424441T2 (no)
DK (1) DK0736004T3 (no)
ES (1) ES2145264T3 (no)
FI (1) FI111718B (no)
GR (1) GR3034134T3 (no)
HK (2) HK1001768A1 (no)
HR (1) HRP950358B1 (no)
HU (1) HU221167B1 (no)
MY (1) MY114178A (no)
NO (1) NO306457B1 (no)
NZ (1) NZ279025A (no)
PL (1) PL185189B1 (no)
PT (1) PT736004E (no)
RU (1) RU2159231C2 (no)
SG (1) SG64903A1 (no)
SK (1) SK282403B6 (no)
TW (1) TW299315B (no)
UA (1) UA45964C2 (no)
WO (1) WO1995017876A2 (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723502A (en) * 1985-07-18 1998-03-03 Proctor; Peter H. Topical spin trap composition and method
US5622994A (en) * 1989-10-17 1997-04-22 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
DK0496796T3 (da) * 1989-10-17 1994-10-03 Oklahoma Med Res Found Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse
US20050107366A1 (en) * 1991-06-18 2005-05-19 Carney John M. Spin trapping pharmaceutical compositions and methods for use thereof
US6002001A (en) * 1991-06-18 1999-12-14 Oklahoma Medical Research Foundation Spin trapping pharmaceutical compositions and methods for use thereof
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
CA2231812C (en) * 1995-09-11 2002-08-06 Hoechst Marion Roussel, Inc. Cyclic nitrones and pharmaceutical compositions containing them
AU7739796A (en) 1995-11-17 1997-06-11 Florida International University Azulenyl nitrone spin trapping agents, methods of making and using same
WO1997038683A1 (en) * 1996-04-17 1997-10-23 Oklahoma Medical Research Foundation Nitrone free radical trap treatment of dementia associated with aids virus (hiv-1) infection
NZ333705A (en) * 1996-07-19 2000-09-29 Centaur Pharmaceuticals Inc Furan nitrone derivatives and medicaments thereof
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
MA26553A1 (fr) 1997-10-17 2004-12-20 Centaur Pharmaceuticals Inc Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
ATE228123T1 (de) * 1998-01-16 2002-12-15 Centaur Pharmaceuticals Inc Thiophennitronderivate
US5998469A (en) * 1998-01-16 1999-12-07 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
CA2323490A1 (en) * 1998-03-13 1999-09-16 Lowell D. Waterbury Inhibition of angiogenesis
EP1077696A1 (en) * 1998-05-19 2001-02-28 Centaur Pharmaceuticals, Inc. Furan nitrone therapeutics for the treatment of inflammatory bowel disease
US6083989A (en) * 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
UA66401C2 (en) 1998-12-02 2004-05-17 Sentor Pharmaceuticals Inc 3,4,5-trisubstituted aryl nitrone compounds and pharmaceutical composition containing the same
US6730700B2 (en) * 1998-12-02 2004-05-04 Renovis, Inc. 3,4,5,-trisubstituted aryl nitrone compounds and pharmaceutical compositions containing the same
ATE312103T1 (de) 1999-01-25 2005-12-15 Nat Jewish Med & Res Center Substituierte porphyrine und deren therapeutische verwendungen
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
BR9904931A (pt) * 1999-10-18 2001-06-12 Sergio Teixeira Ferreira Inibição de amiloidoses
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
WO2001028578A2 (en) * 1999-10-22 2001-04-26 Wrair A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
SE0000056D0 (sv) * 2000-01-10 2000-01-10 Astrazeneca Ab Novel process
SE0000055D0 (sv) * 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
US20020022743A1 (en) * 2000-01-10 2002-02-21 Sergei Pouhov Method for the purification of aryl sulfonic acids and salts
SE0001916D0 (sv) * 2000-05-23 2000-05-23 Astrazeneca Ab Novel formulation
US6664297B1 (en) 2000-10-18 2003-12-16 Universidade Federal Do Rio De Janeiro Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol
AU2002253857A1 (en) 2001-01-08 2002-09-04 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
WO2003010154A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
FR2846968B1 (fr) * 2002-11-08 2005-02-04 Salles Jean Pierre Nouveaux derives amphiphiles de l'alpha-c-phenyl-n-tert- butyl nitrone
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050059638A1 (en) * 2003-08-04 2005-03-17 Kelly Michael G. Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders
US20050182060A1 (en) * 2004-02-13 2005-08-18 Kelly Michael G. 2-Substituted and 4-substituted aryl nitrone compounds
WO2006059252A2 (en) * 2004-11-12 2006-06-08 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
JP2008520647A (ja) * 2004-11-16 2008-06-19 ニューロケム （インターナショナル） リミテッド Ｃｎｓおよびアミロイド関連疾患治療のための化合物
CN101128421A (zh) 2004-12-22 2008-02-20 神经化学（国际）有限公司 治疗淀粉样相关疾病用的方法与组合物
US20060235370A1 (en) * 2005-04-04 2006-10-19 Oblong John E Method of regulating mammalian keratinous tissue
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
WO2007013843A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate n-oxide against myocardial ischaemia
WO2007013841A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimine)methyl) benzene-1,3-disulfonate n-oxide against cerebral oedema
WO2007013844A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-[(tert-butylimino)benzene-1,3-disulfonate n-oxide against nausea
WO2007013842A1 (en) * 2005-07-26 2007-02-01 Astrazeneca Ab Use of 4-((tert-butylimino)methyl) benzene-1,3-disulfonate n-oxide against maemorrhagic changes in the brain
CA2634871A1 (en) * 2005-12-22 2007-11-08 Neurochem (International) Limited Treatment of renal disorders, diabetic nephopathy and dyslipidemias
JP5236641B2 (ja) * 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
JP5607930B2 (ja) 2006-10-12 2014-10-15 ビーエイチアイ リミテッド パートナーシップ ３−アミノ−１−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体
JP2010529947A (ja) * 2006-12-22 2010-09-02 ベラス ヘルス（インターナショナル）リミテッド 代謝性疾患および糖尿病を治療するための方法、化合物、および組成物
US20090082454A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched disufenton
EP4309627A3 (en) 2007-09-26 2024-07-17 St. Jude Medical, LLC Collapsible prosthetic heart valves
US8227517B2 (en) * 2008-02-12 2012-07-24 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
RU2506083C2 (ru) * 2008-05-23 2014-02-10 Нэшнл Джуиш Хелт Способ лечения поражений, ассоциированных с воздействием алкилирующих веществ
US8633249B2 (en) 2008-09-02 2014-01-21 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
US10555915B2 (en) * 2009-08-24 2020-02-11 Hough Ear Institute Methods for treating acute acoustic trauma
EP2670403B1 (en) * 2011-02-04 2021-08-18 Hough Ear Institute Methods for treating brain injury
JP2019537582A (ja) * 2016-10-31 2019-12-26 ハフ イアー インスティテュート シナプス形成および神経突起形成を増強するための方法
US11020354B2 (en) 2017-01-19 2021-06-01 Otologic Pharmaceuticals, Inc. Formulations of n-acetylcysteine and uses thereof
US11660280B2 (en) 2017-09-20 2023-05-30 Oklahoma Medical Research Foundation Treatment of drug resistant gliomas
US10829441B2 (en) 2017-11-14 2020-11-10 The University Of Toledo Reactive oxygen species-sensitive nitric oxide synthase inhibitors for the treatment of ischemic stroke
WO2019213245A1 (en) 2018-05-03 2019-11-07 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025032A (en) * 1989-10-17 1991-06-18 Oklahoma Medical Research Foundation Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration
DK0496796T3 (da) * 1989-10-17 1994-10-03 Oklahoma Med Res Found Fremgangsmåde og præparater til inhibering af sygdomme i forbindelse med oxidativ beskadigelse
ATE209908T1 (de) * 1991-06-18 2001-12-15 Oklahoma Med Res Found RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps

Also Published As

Publication number Publication date
SK78896A3 (en) 1997-09-10
US5508305A (en) 1996-04-16
MY114178A (en) 2002-08-30
ES2145264T3 (es) 2000-07-01
SG64903A1 (en) 1999-05-25
WO1995017876A3 (en) 1995-08-10
EP0736004B1 (en) 2000-05-10
CZ289629B6 (cs) 2002-03-13
JPH09507232A (ja) 1997-07-22
JP2004075696A (ja) 2004-03-11
PL315154A1 (en) 1996-10-14
CN1156447A (zh) 1997-08-06
US5475032A (en) 1995-12-12
HK1008294A1 (en) 1999-05-07
GR3034134T3 (en) 2000-11-30
NO962637L (no) 1996-08-13
FI962589A0 (fi) 1996-06-20
TW299315B (no) 1997-03-01
HK1001768A1 (en) 1998-07-10
CN1070176C (zh) 2001-08-29
PL185189B1 (pl) 2003-03-31
HRP950358A2 (en) 1997-08-31
UA45964C2 (uk) 2002-05-15
HU9601739D0 (en) 1996-08-28
HU221167B1 (en) 2002-08-28
AU679835B2 (en) 1997-07-10
ATE192736T1 (de) 2000-05-15
DE69424441D1 (de) 2000-06-15
BR9408378A (pt) 1997-08-19
CA2179521C (en) 2002-03-19
RU2159231C2 (ru) 2000-11-20
WO1995017876A2 (en) 1995-07-06
BR1100626A (pt) 1999-11-23
PT736004E (pt) 2000-09-29
US5488145A (en) 1996-01-30
US5780510A (en) 1998-07-14
EP0736004A1 (en) 1996-10-09
CA2179521A1 (en) 1995-07-06
JP3412821B2 (ja) 2003-06-03
NZ279025A (en) 1998-02-26
FI111718B (fi) 2003-09-15
JP2001010953A (ja) 2001-01-16
NO306457B1 (no) 1999-11-08
AU1552795A (en) 1995-07-17
HRP950358B1 (en) 2001-04-30
FI962589A (fi) 1996-08-20
DE69424441T2 (de) 2000-10-12
CZ177596A3 (en) 1996-12-11
SK282403B6 (sk) 2002-01-07
DK0736004T3 (da) 2000-10-09
KR100370522B1 (ko) 2003-05-16
HUT76788A (en) 1997-11-28

Similar Documents

Publication Publication Date Title
NO962637L (no) 2,4-disulfonylfenylbutylnitron, salter derav og anveldelse som farmasöytiske midler
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
NZ512883A (en) 2-oxoquinoline compounds and medicinal uses thereof
UA29469C2 (uk) Ліпосомальна фармацевтична композиція для внутрішньовенного введення
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
HUP0204391A2 (en) The use of mirtazapine for the preparation of pharmaceutical composition suitable for the treatment of sleep disorders
NO955313D0 (no) Anvendelse av ropivacain i fremstillingen av et farmasöytikum med analgetisk effekt som har minimal motorisk blokkering
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
AR035986A1 (es) Uso de derivados anti-convulsivos para la manufactura de un medicamento util para el tratamiento del temblor esencial
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine
ITMI922040A1 (it) Composizioni farmaceutiche per il trattamento di stati di iperaggregabilita' piastrinica